Editor’s Note: Jorge Conde is Andreessen Horowitz’ newest general partner on our bio fund, which was formally established two years ago with general partner Vijay Pande to lead the firm’s investments at the cross section of biology, computer science, and healthcare. Before joining a16z, Conde was at Syros Pharmaceuticals — where he most recently served as Chief Strategy Officer (and before that, as CFO and Chief Product Officer) — advancing a new wave of medicines to treat cancer and other diseases through a novel gene control platform. He also co-founded, with renowned Harvard and MIT genetics professor George Church, genomics interpretation company Knome (acquired by Tute Genomics in 2015). With degrees in both business and biology, Conde has also worked in marketing, operations, and,...

Editor’s Note: Jorge Conde is Andreessen Horowitz’ newest general partner on our bio fund, which was formally established two years ago with general partner Vijay Pande to lead the firm’s investments at the cross section of biology, computer science, and healthcare. Before joining a16z, Conde was at Syros Pharmaceuticals — where he most recently served as Chief Strategy Officer (and before that, as CFO and Chief Product Officer) — advancing a new wave of medicines to treat cancer and other diseases through a novel gene control platform. He also co-founded, with renowned Harvard and MIT genetics professor George Church, genomics interpretation company Knome (acquired by Tute Genomics in 2015). With degrees in both business and biology, Conde has also worked in marketing, operations, and, biotech investment banking. Currently based in Boston, he will soon move to California.